NEWS: 公告在東京證券交易所JASDAQ標準市場新上市


全球適體市場-預測 (2021-2026)

Global Aptamers Market - Forecasts from 2021 to 2026

出版商 Knowledge Sourcing Intelligence 商品編碼 1023146
出版日期 內容資訊 英文 114 Pages
商品交期: 最快1-2個工作天內
全球適體市場-預測 (2021-2026) Global Aptamers Market - Forecasts from 2021 to 2026
出版日期: 2021年07月09日內容資訊: 英文 114 Pages

2019 年全球適配體市場規模估計為 1,068,800,000 美元,預計在預測期內將快速增長。

適配子是單鏈 DNA 或 RNA,由於它們能夠形成環和螺旋,因此具有形成各種形狀的特性。一切,例如適體的核酸如何折疊以及適體所在基質的狀態,都會影響與靶標的結合。適配體用途廣泛,可與高選擇性和特異性靶標結合,如蛋白質、□和糖。目前,適配體用於各種疾病的診斷和小分子的檢測。


在過去幾年中,大公司對市場產生了巨大影響。加速研發投入預計將對整體市場增長產生積極影響。 Aptamer 是市場上的領先公司,從事適體開發已超過 25 年。該公司已開發出與蛋白質、小分子、組織、細胞等特異性結合的高親和力適體。該公司還為治療學、生物技術和診斷應用創造了尖端、先進的元素。預計這些趨勢和發展將對預測期內的市場產生積極影響。



第 1 章介紹

  • 市場定義
  • 市場細分

第 2 章調查方法

  • 調查數據
  • 假設

第 3 章執行摘要

  • 調查亮點

第 4 章市場動態

  • 市場驅動因素
  • 市場限制
  • 波特五力分析
    • 供給側的談判權
    • 買方談判權
    • 新進入者的威脅
    • 替代威脅
    • 行業競爭對手之間的敵對關係
  • 產業價值鏈分析

第 5 章按類型劃分的全球適體市場分析

  • 簡介
  • 基於 DNA 的適配子
  • 基於 RNA 的適配體
  • 基於□的適體

第 6 章全球適配體市場應用分析

  • 簡介
  • 治療
  • 診斷
  • 其他

第 7 章終端用戶全球適配體市場分析

  • 簡介
  • 研究機構
  • 生物科技公司
  • 製藥公司

第 8 章按地區分列的全球適體市場分析

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 法國
    • 德國
    • 意大利
    • 其他
  • 中東和非洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 泰國
    • 台灣
    • 印度尼西亞
    • 其他

第 9 章競爭環境與分析

  • 主要參與者和策略分析
  • 新興參與者和市場盈利能力
  • 合併、收購、協議和合作
  • 供應商競爭力矩陣

第 10 章公司簡介

  • Aptamer Sciences
  • Raptamer Discovery Group
  • Aptagen LLC
  • Veraptus
  • AMS Biotechnology Limited
  • Aptamer Group
  • Novaptech
  • Elixin Pharma
  • Base Pair Technologies
  • Aptus Biotech
Product Code: KSI061611593

The global aptamers market is estimated to be valued at US$1,068.804 million in 2019 and is projected to grow rapidly during the forecast period. Aptamers are single-stranded DNA or RNA and have the property to assume a variety of shapes due to their ability to form loops and helices. The way aptamers fold, the order of the nucleic acids, and the conditions of the matrix they are in, all contribute to binding a target. Owing to their extreme versatility they bind to the target that is highly selective and specific including proteins, peptides, and carbohydrates. Aptamers are currently being used for the diagnosis of various diseases and the detection of small molecules.

Aptamers may be used as pharmaceutical lead selection reagents and functional proteomic levels. The growth in the market may be attributed to the advantages of the aptamer over antibodies such as low cost and high efficiency, coupled with the diverse range of applications offered by the aptamers. Continuous advancement in technologies along with its quick implementation is expected to boost the market growth during the given period. However, a lack of skilled professionals may hamper the market growth during the given period. Major companies have been making a significant impact in the market, in the past few years. The acceleration in the investments in Research and Development is expected to make a positive impact on the overall market growth. Aptagen, a key player in the market, has been involved in aptamer development, over 25 years. The company has been generating specifically binding and high-affinity aptamers, for proteins, small molecules, tissues, and cells. The company has also been producing state of art and advanced elements for therapeutics, bio-industrial and diagnostic applications. These trends and developments are expected to have a positive impact on the market, during the forecast period.

Rising R&D investments in biotechnology and pharmaceutical industries.

The market is expected to surge in the coming years, due to the growth in R&D investments in the pharmaceutical and biotechnology industries. The research-based pharmaceutical and biotechnology industry plays a significant role in the enhancement of a specific region, advancing competitive index, and is essential to the growth of the global economy. According to the European Federation of Pharmaceutical Industries and Associations, the total R&D expenditure in the pharmaceutical sector in Europe had been over EUR35 billion, in the year 2019. India is also expected to play a major role in the overall market growth. The country has been among the top 12 destinations for biotechnology, globally, and has around a 3% share in the biotechnology industry, according to the data given by the National Investment Promotion & Facilitation Agency. Other countries, such as China and the United States are also expected to have a major role in the overall market growth. The United States has been a major destination for research and development. In 2004, the first and novel aptamer therapeutic product, which has been called Macugen was approved by the United States of Food and Drugs Administration. China has become one of the biggest healthcare markets, globally. According to the country's government, the pharmaceutical market had been worth more than US$100 billion in the year 2019. The country has also introduced several reforms to attract biotech investors. These trends are expected to have a positive impact on the market, in the coming years.

Latest Developments

  • In June 2021, Aptamer Group, a producer, and developer of Optimer Therapeutics, and PinotBio, a clinical-stage and a major oncology biotech firm, announced that they had entered into a joint strategic partnership and collaboration agreement, intending to develop optimal drug conjugates for the targeted drug delivery system. The novel technology would combine Aptamer's Group' Optimer technology, with chemotherapeutic FL-188 of PinotBio. Optimer therapeutics are also known as optimized aptamer solutions. This development is expected to have a positive impact on the market, in the coming years.
  • In April 2021, a research team from India's Vellore Institute of Technology announced that they had bagged a project, which had been funded by the Science and Engineering Research Board of the Department of Science and Technology, intending to produce and develop an aptamer-based POC diagnostic kit for detecting COVID-19 strains. The research team would use an aptamer-based biosensor, which contains the biorecognition element, to produce a detectable signal after detecting the target.
  • In May 2021, Aptamer Group announced that it had extended its current and ongoing agreement with a major pharmaceutical firm, called AstraZeneca. The current agreement would allow the existing collaboration to evaluate the potential use of Optimer-based strategies to explore the feasibility of the development of next-generation drug delivery vehicles and target renal cells, Optimer-drug conjugates. This development is expected to have a positive impact on the market, in the coming years.

Market Segmentation:

  • By Type
  • DNA based Aptamers
  • RNA based Aptamers
  • Peptide-based Aptamers
  • By Application
  • Therapeutic
  • Diagnostics
  • Others
  • By End User
  • Research Institutes
  • Biotechnology Companies
  • Pharmaceutical Companies
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Others
  • Middle East and Africa
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Thailand
  • Taiwan
  • Indonesia
  • Others

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Global Aptamers Market Analysis, By Type

  • 5.1. Introduction
  • 5.2. DNA based Aptamers
  • 5.3. RNA based Aptamers
  • 5.4. Peptide based Aptamers

6. Global Aptamers Market Analysis, By Application

  • 6.1. Introduction
  • 6.2. Therapeutic
  • 6.3. Diagnostics
  • 6.4. Others

7. Global Aptamers Market Analysis, By End-User

  • 7.1. Introduction
  • 7.2. Research Institutes
  • 7.3. Biotechnology Companies
  • 7.4. Pharmaceutical Companies

8. Global Aptamers Market Analysis, By Geography

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. UK
    • 8.4.2. France
    • 8.4.3. Germany
    • 8.4.4. Italy
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. Thailand
    • 8.6.5. Taiwan
    • 8.6.6. Indonesia
    • 8.6.7. Others

9. Competitive Environment and Analysis

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. Company Profiles

  • 10.1. Aptamer Sciences
  • 10.2. Raptamer Discovery Group
  • 10.3. Aptagen LLC
  • 10.4. Veraptus
  • 10.5. AMS Biotechnology Limited
  • 10.6. Aptamer Group
  • 10.7. Novaptech
  • 10.8. Elixin Pharma
  • 10.9. Base Pair Technologies
  • 10.10. Aptus Biotech